{"id":795017,"date":"2024-12-16T08:06:08","date_gmt":"2024-12-16T13:06:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/"},"modified":"2024-12-16T08:06:08","modified_gmt":"2024-12-16T13:06:08","slug":"immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/","title":{"rendered":"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>Findings published in\u00a0<em>Science Immunology<\/em> resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep\u2019s anti-LAG-3 small molecule program<\/li>\n<li>Data also supports eftilagimod alfa\u2019s (efti) preferential binding to a subset of MHC Class II molecules on antigen-presenting cells leading to their activation<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>SYDNEY, AUSTRALIA, Dec.  16, 2024  (GLOBE NEWSWIRE) &#8212; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Eo2TeemOYneGIleX7tEJ8Qu5yAgVGCsw3eNIjzMSiyslBvf4ys8_dl_nY4HCspQt1c5QRM3XPZU7e9FQstRRuQ==\" rel=\"nofollow\" target=\"_blank\">Immutep Limited<\/a> (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new findings published in <em>Science Immunology<\/em> that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans. The publication is the first to show the crystal structure of a human LAG-3\/HLA-II complex and provides a better foundation for development of blocking LAG-3 therapeutics, including Immutep\u2019s anti-LAG-3 small molecule program.<\/p>\n<p align=\"justify\">Under the oversight of Professor Jamie Rossjohn FAA FRS, at Monash University\u2019s Biomedicine Discovery Institute (BDI), and in collaboration with Immutep, this breakthrough is an exemplar of the importance of industry-academia alliances<em>. <\/em>The LAG-3 immune control mechanism is the exclusive focus of Immutep across both cancer and autoimmunity and a clinically validated target of deep interest throughout the academic, medical, and industry sectors.<\/p>\n<p align=\"justify\">\n        <strong>Dr. Jan Petersen, first author of the study, said<\/strong>: \u201cThe way the PD-1 and CTLA-4 immune checkpoint molecules bind to their respective ligands has been resolved for many years. However, the resolution of the interface between another important checkpoint molecule, LAG-3, and its main ligands, HLA-II molecules, has remained elusive. Solved using data collected at the Australian Synchrotron, a structure of a LAG-3\/HLA-II complex provides a structural foundation to harness rationally for future development of antibodies and small molecule therapeutics designed to block LAG-3 activity.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Dr. Fr\u00e9d\u00e9ric Triebel, Immutep\u2019s CSO, added<\/strong>: \u201cIt is thrilling to be able to see and analyze the interactions taking place at the interface between the soluble homodimeric LAG-3 protein and its main ligand. We now better understand how efti uniquely acts as an MHC-II agonist by preferentially binding to a subset of MHC-II molecules clustered in lipid raft microdomains on the surface of antigen-presenting cells. These findings add to the strong foundation of our work with Professor Rossjohn and his team to develop a deeper understanding of the structure and function of the LAG-3 immune control mechanism, particularly as it relates to our anti-LAG-3 small molecule program.\u201d<\/p>\n<p align=\"justify\">The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zme_J36j1GplCGqPrlyJNylSaH_qgsjTIDQy3xpxbcOsSLhLOZK0cmzWhrgMD7qwW7wPRZImI8eRg-yWBF68t1Lsj1H4q53u_ZI-iZkjJ_pk4N6bbRRvoTXdm3CtEGsn2X1v3Qe8URygAyozVGww-YaLsFprdqbhGUymXCnP0zALXux2MOUuHBwAMGdFBD8m\" rel=\"nofollow\" target=\"_blank\"><em>Crystal Structure of the Human LAG-3\u2013HLA-DR1\u2013Peptide Complex<\/em><\/a> publication details how LAG-3 engages two HLA-II molecules (see Figure 1). The data in the publication supports efti\u2019s (soluble LAG-3) preferential binding to a subset of MHC-II molecules on antigen-presenting cells leading to their activation.<\/p>\n<p align=\"justify\" \/>\n<p align=\"justify\">\n        <strong>Figure 1:<\/strong><br \/>\n        <em>Human LAG-3 homodimer (with domains D1, D2, D3 and D4) <\/em><br \/>\n        <em>binding to two separate HLA-II (MHC-II) molecules on the surface of an antigen-presenting cell (APC), imposing a distinct 38\u00b0 offset angle. This figure has been modified from the original Figure 1c of Petersen et al to aid visualisation.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>About the Monash Biomedicine Discovery Institute<\/strong><br \/>\n        <br \/>Committed to making the discoveries that will relieve the future burden of disease, the Monash Biomedicine Discovery Institute (BDI) at Monash University brings together more than 120 internationally-renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.<\/p>\n<p align=\"justify\">\n        <strong>About Immutep<\/strong><br \/>\n        <br \/>Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b0k7G4VcITUXODEvKP9CJHKtNTXBMbJG2jT_pQ39MSJMr_h6kxyS6n2JhTv6MHAICGrFn4-bYmA5-6852N6mow==\" rel=\"nofollow\" target=\"_blank\">www.immutep.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Australian Investors\/Media:<\/strong><br \/>\n        <br \/>Catherine Strong, Sodali &amp; Co<br \/>+61 (0)406 759 268; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=n4oOdDlqhiQ8yXg0fmADyuDiC91-X4i5j-W0TqnXq4XfT8Xoz-Y5LvIRL9dcWos7PvUnJ-xk4YDBVspBKWqwh3PgADVRLZs_UqxmW_Ugaz2u9kSawwa0xGCZ56ID-_u5\" rel=\"nofollow\" target=\"_blank\">catherine.strong@sodali.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>U.S. Media:<\/strong><br \/>\n        <br \/>Chris Basta, VP, Investor Relations and Corporate Communications<br \/>+1 (631) 318 4000; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SVt0joXRW09SvDzPkPzNyt6nV-NaZQmce4Rb6tnJgRDVki1V7umJFrJ9rj8d0wGObb9av_3UAwy9VoMlOB27MUKPXZyGlzHjhlFm481NF7M=\" rel=\"nofollow\" target=\"_blank\">chris.basta@immutep.com<\/a>\u00a0<br \/>ABN: 90 009 237 889<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWY0NDNjZGEtMjQ3NS00YzY4LWE2MzMtNWViOTdkODdhOTU1LTEwMzE0MDU=\/tiny\/Immutep-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Findings published in\u00a0Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep\u2019s anti-LAG-3 small molecule program Data also supports eftilagimod alfa\u2019s (efti) preferential binding to a subset of MHC Class II molecules on antigen-presenting cells leading to their activation SYDNEY, AUSTRALIA, Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans. The publication &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-795017","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Findings published in\u00a0Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep\u2019s anti-LAG-3 small molecule program Data also supports eftilagimod alfa\u2019s (efti) preferential binding to a subset of MHC Class II molecules on antigen-presenting cells leading to their activation SYDNEY, AUSTRALIA, Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans. The publication &hellip; Continue reading &quot;Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-16T13:06:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II\",\"datePublished\":\"2024-12-16T13:06:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/\"},\"wordCount\":717,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/\",\"name\":\"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=\",\"datePublished\":\"2024-12-16T13:06:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/","og_locale":"en_US","og_type":"article","og_title":"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II - Market Newsdesk","og_description":"Findings published in\u00a0Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep\u2019s anti-LAG-3 small molecule program Data also supports eftilagimod alfa\u2019s (efti) preferential binding to a subset of MHC Class II molecules on antigen-presenting cells leading to their activation SYDNEY, AUSTRALIA, Dec. 16, 2024 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans. The publication &hellip; Continue reading \"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-16T13:06:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II","datePublished":"2024-12-16T13:06:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/"},"wordCount":717,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/","name":"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=","datePublished":"2024-12-16T13:06:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxOTUzMyM2NjM4MzgzIzIwMTk4MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-and-monash-university-announce-first-publication-detailing-how-human-lag-3-binds-to-mhc-class-ii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=795017"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795017\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=795017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=795017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=795017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}